Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery

Area of Science:

• Biotechnology
• Immunology
• Drug Discovery

Background:

• Ongoing debate exists regarding the ethical and practical implications of antibody discovery methods.
• Traditional animal immunization and in vitro recombinant display technologies are compared for their benefits and drawbacks.
• The number of animals used in preclinical studies significantly outweighs those used in initial antibody discovery.

Purpose of the Study:

• To evaluate the impact of different antibody discovery strategies on overall animal consumption.
• To emphasize the importance of antibody quality control in reducing animal use.
• To explore the future role of machine learning in antibody discovery.

Main Methods:

• Comparative analysis of animal immunization versus in vitro recombinant antibody repertoire selection.
• Assessment of animal consumption across different stages of antibody development.
• Anticipation of machine learning integration into antibody discovery pipelines.

Main Results:

• The number of animals sacrificed during preclinical studies is substantially higher than those used in antibody discovery.
• Enhancing antibody quality control prior to in vivo testing presents a more significant opportunity for animal welfare improvements.
• Both animal immunization and recombinant display methods offer distinct advantages for generating fit-for-purpose antibodies.

Conclusions:

• Prioritizing antibody quality control in preclinical stages is crucial for reducing overall animal consumption in research.
• Both traditional and novel antibody discovery techniques have unique strengths.
• Machine learning is poised to significantly advance and refine antibody discovery processes.